Over the summer 23andMe launched a collaborative study with Pfizer to study the research inflammatory bowel disease (IBD).
We’ve been encouraged by the number of people diagnosed with either Crohn’s disease and ulcerative colitis who have joined the study. On top of the research we’re doing, we also want to raise awareness about these debilitating digestive conditions and Inflammatory Bowel Disease (IBD) more broadly.
More than 1.4 million Americans suffer from IBD, while in Europe two in every 1,000 people are affected. The incidence and prevalence of IBD, is rising even in Asia where the rates have historically been low.
Not to be confused with irritable bowel syndrome, IBD is a very serious and sometimes crippling condition. Symptoms can include abdominal pain, persistent diarrhea, bleeding, and severe weight loss.